Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 8, 2010
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapyKi Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, et al.
Korean Journal of Pathology|October 31, 2012
Frequency of BRAF Mutation and Clinical Relevance for Primary MelanomasHyoun Wook Lee, Ki Hoon Song, Jin Woo Hong, et al.
Cancer Research and Treatment|July 2, 2015
Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal CancerKyung A Kwon, Jeanho Yun, Sung Yong Oh, et al.
Cancer Research and Treatment|August 4, 2011
Predictive value of in vitro adenosine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-Fluorouracil after curative resectionJi Hyun Lee, Min-Chan Kim, Sung Yong Oh, et al.
Japanese Journal of Clinical Oncology|January 24, 2008
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascitesSung Yong Oh, Hyuk-Chan Kwon, Suee Lee, et al.
Asia-Pacific Journal of Clinical Oncology|December 1, 2010
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissectionHyuk-Chan Kwon, Min Chan Kim, Ki Han Kim, et al.
Oncology Letters|June 11, 2017
Clinical significance of coagulation factors in operable colorectal cancerSuee Lee, Seok Jae Huh, Sung Yong Oh, et al.
The Oncologist|October 2, 2015
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)Su Jin Lee, Tae Min Kim, Yu Jung Kim, et al.
Cancer Research and Treatment|January 17, 2012
A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal CarcinomatosisDong Hyun Lee, Sung Yong Oh, Yu Rim Lee, et al.
American Journal of Clinical Oncology|September 23, 2009
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancerByung Geun Kim, Sung Yong Oh, Hyuk-Chan Kwon, et al.
Pageof 9